SCHEMBL6339183

SCHEMBL6339183

CCOC(=O)C1Cc2cccc(OC)c2NC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 4/20 0.48
HSD17B10 Q99714 3/20 0.48
MEN1 O00255 3/20 0.48
HPGD P15428 2/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 2/20 0.48
RAB9A P51151 1/20 0.46
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
DHFR P00374 1/20 0.43
LMNA P02545 2/20 0.41
CTDSP1 Q9GZU7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6341721 0.83 HTR5A (0.43) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL7076035 0.81 LMNA (0.41) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL20478826 0.80 KDM4E (0.49) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL9370579 0.79 KDM4E (0.55) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL10361090 0.78 KDM4E (0.53) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL10319302 0.78 KDM4E (0.52) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL2062381 0.78 MTNR1A (0.47) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL10274508 0.74 HTR5A (0.47) ALDH1A1POLBHTR5A
SCHEMBL7945190 0.73 ALDH1A1 (0.48) ALDH1A1KMT2AKDM4EHSD17B10MEN1
SCHEMBL17049209 0.73 ALDH1A1 (0.48) ALDH1A1KMT2AKDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6869960-B2 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor PFIZER INC. (US) 2005-03-22 US disclosed
EP-1470126-A1 N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR PFIZER INC. (US) 2004-10-27 EP disclosed
US-20030158219-A1 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor ITO FUMITAKA (JP) 2003-08-21 US disclosed
WO-2003064425-A1 N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR PFIZER JAPAN INC. (JP) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158219-A1 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor OGFRL1, OXER1, ORMDL3 ALDH1A1 306/4885KMT2A 3375/4885KDM4E 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.